Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
EF Hutton Annual Global Conference Details:
Format: |
In-person one-on-one meetings (no general presentations) |
Location: |
|
R egistration: |
Visit the conference website |
Presentation*: |
|
Format: |
Presentations and one-on-one meetings |
Location : |
Nasdaq Global Headquarters, |
R egistration: |
Visit the conference website |
*Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.
About
Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. The Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with
Investor Contact:
ir@citiuspharma.com
908-967-6677 x113
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-ef-hutton-and-hc-wainwright-investor-conferences-302141737.html
SOURCE